Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

FDA Approves Transdermal Patch To Treat Alzheimer’s-Related Dementia

Corium, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Corium’s ADLARITY (donepezil transdermal system) as a treatment for those with mild, moderate, or severe dementia of the Alzheimer’s type. ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. This delivery mechanism results in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Corium plans to launch sales of the new medication in early fall 2022.

Corium, Inc. is a commercial-stage biopharmaceutical company leading the development and commercialization of novel central . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!